Prognostic factors in the palliation of pancreatic cancer

被引:96
作者
Engelken, FJF [1 ]
Bettschart, V [1 ]
Rahman, MQ [1 ]
Parks, RW [1 ]
Garden, OJ [1 ]
机构
[1] Univ Edinburgh, Dept Clin & Surg Sci Surg, Royal Infirm Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2003年 / 29卷 / 04期
关键词
pancreatic neoplasms; palliative care; treatment outcome; prognosis;
D O I
10.1053/ejso.2002.1405
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Few patients with pancreatic cancer are eligible for resection. In the remainder, estimation of prognosis is important to optimise various aspects of care, including palliation of biliary obstruction and trial of chemotherapy. The aim is to evaluate the Prognostic significance of clinical and laboratory variables in patients with unresectable pancreatic cancer. Methods: Information was gathered retrospectively for 325 patients with unresectable pancreatic cancer who underwent palliative interventions, including surgical bypass, endoscopic or percutaneous stenting or who received supportive care only. Results: Histological proof was obtained in 182 patients (56%). Median survival was 5.7 months. Absence of therapeutic intervention, leukocytosis (WCC greater than or equal to 11 x 10(9)/l), gamma glutamyl transferase (gammaGT) > 165 U/L, prothrombin time ratio > 1.1, and C-reactive protein (CRP) greater than or equal to5 mg/dL were associated with shorter survival on univariate analysis. Only absence of therapeutic intervention, leukocytosis, and gammaGT > 165 U/L reached significance on multivariate analysis. In the 51 patients in whom serum CRP was available, CRP was the only significant predictor of survival on multivariate analysis. Conclusions: Leukocytosis, elevated gammaGT and raised CRP predict shorter survival and may help to guide the choice of palliative intervention for patients with unresectable pancreatic cancer. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 35 条
  • [1] RANDOMIZED TRIAL OF ENDOSCOPIC ENDOPROSTHESIS VERSUS OPERATIVE BYPASS IN MALIGNANT OBSTRUCTIVE-JAUNDICE
    ANDERSEN, JR
    SORENSEN, SM
    KRUSE, A
    ROKKJAER, M
    MATZEN, P
    [J]. GUT, 1989, 30 (08) : 1132 - 1135
  • [2] Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer
    Barber, MD
    Ross, JA
    Fearon, KCH
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 35 (02): : 106 - 110
  • [3] BASSO D, 1988, ANN CLIN RES, V20, P414
  • [4] BORNMAN PC, 1986, LANCET, V1, P69
  • [5] TREATMENT AND SURVIVAL IN 13560 PATIENTS WITH PANCREATIC-CANCER, AND INCIDENCE OF THE DISEASE, IN THE WEST MIDLANDS - AN EPIDEMIOLOGIC-STUDY
    BRAMHALL, SR
    ALLUM, WH
    JONES, AG
    ALLWOOD, A
    CUMMINS, C
    NEOPTOLEMOS, JP
    [J]. BRITISH JOURNAL OF SURGERY, 1995, 82 (01) : 111 - 115
  • [6] Brennan MF, 1996, ANN SURG, V223, P506, DOI 10.1097/00000658-199605000-00006
  • [7] SURVIVAL IN 1001 PATIENTS WITH CARCINOMA OF THE PANCREAS
    CONNOLLY, MM
    DAWSON, PJ
    MICHELASSI, F
    MOOSSA, AR
    LOWENSTEIN, F
    [J]. ANNALS OF SURGERY, 1987, 206 (03) : 366 - 373
  • [8] METALLIC MESH STENTS - IS THE EXPANSE WORTH THE EXPENSE
    COTTON, PB
    [J]. ENDOSCOPY, 1992, 24 (05) : 421 - 423
  • [9] FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO
  • [10] 2-9